Literature DB >> 9517443

5-HT autoreceptors in the regulation of 5-HT release from guinea pig raphe nucleus and hypothalamus.

C Moret1, M Briley.   

Abstract

5-HT autoreceptors involved in the regulation of 5-HT release in the guinea pig dorsal raphe nucleus have been studied in comparison with those in the hypothalamus. In vitro release was measured in slices of raphe and hypothalamus prelabelled with [3H]5-HT, superfused with Krebs solution and depolarized electrically. The non-selective 5-HT receptor agonist, 5-carboxamidotryptamine (5-CT) (0.1-10 nM for raphe: 1-100 nM for hypothalamus) and antagonist, methiothepin (10-1000nM), decreased and increased, respectively, the release of [3H]5-HT evoked by electrical stimulation in either of these regions when given alone. The selective 5-HT1B/D receptor antagonist, GR127935 (100-1000 nM), and the 5-HT1D receptor antagonist, ketanserin (300-1000 nM), had no significant effect on this release in either of these regions. Methiothepin and GR127935 (100-1000 nM) shifted to the right the concentration-effect curve of 5-CT in both the raphe and the hypothalamus. At 300 nM, ketanserin shifted to the right the concentration-effect curve of 5-CT in the raphe but did not modify the 5-CT curve in the hypothalamus. In microdialysis experiments ketanserin, applied locally at 10 microM, increased the extracellular levels of 5-HT in the dorsal raphe nucleus of the freely moving guinea pig, whereas 5-HT levels were unchanged in the hypothalamus. Ketanserin at 1 microM did not affect the decrease in 5-HT output induced by the selective 5-HT1B/D receptor agonist, naratriptan (used at 10 microM in raphe and 0.1 microM in hypothalamus), in the raphe or the hypothalamus. In the raphe, WAY100635, a 5-HT1A receptor antagonist, at 1 microM, did not prevent naratriptan (10 microM) from reducing the extracellular levels of 5-HT. These results suggest that, in the conditions used in this study, the release of 5-HT in the dorsal raphe nucleus is possibly modulated in part by 5-HT1B receptors but essentially the control is through 5-HT receptors whose subtype is still to be determined. In the hypothalamus, however, it is clear that only 5-HT1B receptors are involved in the modulation of 5-HT neurotransmission.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9517443     DOI: 10.1016/s0028-3908(97)00145-7

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  6 in total

1.  SB-272183, a selective 5-HT(1A), 5-HT(1B) and 5-HT(1D) receptor antagonist in native tissue.

Authors:  J Watson; C Roberts; C Scott; I Kendall; L Collin; N C Day; M H Harries; E Soffin; C H Davies; A D Randall; T Heightman; L Gaster; P Wyman; C Parker; G W Price; D N Middlemiss
Journal:  Br J Pharmacol       Date:  2001-07       Impact factor: 8.739

2.  Serotonergic modulation across sensory modalities.

Authors:  Tyler R Sizemore; Laura M Hurley; Andrew M Dacks
Journal:  J Neurophysiol       Date:  2020-05-13       Impact factor: 2.714

Review 3.  Preclinical neuropharmacology of naratriptan.

Authors:  Geoffrey A Lambert
Journal:  CNS Drug Rev       Date:  2005

Review 4.  Tolerability of the triptans: clinical implications.

Authors:  Giuseppe Nappi; Giorgio Sandrini; Grazia Sances
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

Review 5.  Genetic variation in cortico-amygdala serotonin function and risk for stress-related disease.

Authors:  Andrew Holmes
Journal:  Neurosci Biobehav Rev       Date:  2008-03-26       Impact factor: 8.989

6.  Monitoring serotonin signaling on a subsecond time scale.

Authors:  Elyse C Dankoski; R Mark Wightman
Journal:  Front Integr Neurosci       Date:  2013-06-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.